@article{6e0dd15d0d9f49d29ec6c703efd80e11,
title = "International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100)",
abstract = "Multiple myeloma is the most common indication for high-dose chemotherapy with autologous stem cell support (ASCT) in North America today. Stem cell procurement for ASCT has most commonly been performed with stem cell mobilization using colony-stimulating factors with or without prior chemotherapy. The target CD34+ cell dose to be collected as well as the number of apheresis performed varies throughout the country, but a minimum of 2 million CD34+ cells/kg has been traditionally used for the support of one cycle of high-dose therapy. With the advent of plerixafor (AMD3100) (a novel stem cell mobilization agent), it is pertinent to review the current status of stem cell mobilization for myeloma as well as the role of autologous stem cell transplantation in this disease. On June 1, 2008, a panel of experts was convened by the International Myeloma Foundation to address issues regarding stem cell mobilization and autologous transplantation in myeloma in the context of new therapies. The panel was asked to discuss a variety of issues regarding stem cell collection and transplantation in myeloma especially with the arrival of plerixafor. Herein, is a summary of their deliberations and conclusions.",
author = "S. Giralt and Stadtmauer, {E. A.} and Harousseau, {J. L.} and A. Palumbo and W. Bensinger and Comenzo, {R. L.} and S. Kumar and Munshi, {N. C.} and A. Dispenzieri and R. Kyle and G. Merlini and {San Miguel}, J. and H. Ludwig and R. Hajek and S. Jagannath and J. Blade and S. Lonial and Dimopoulos, {M. A.} and H. Einsele and B. Barlogie and Anderson, {K. C.} and M. Gertz and M. Attal and P. Tosi and P. Sonneveld and M. Boccadoro and G. Morgan and O. Sezer and Mateos, {M. V.} and M. Cavo and D. Joshua and I. Turesson and W. Chen and K. Shimizu and R. Powles and Richardson, {P. G.} and R. Niesvizky and Rajkumar, {S. V.} and Durie, {B. G.M.}",
note = "Funding Information: S Giralt: Advisory Board for Celgene, Millennium, Novartis, and Genzyme; E Stadtmauer: Advisory Board for Genzyme; J Harousseau: Received Honoraria from Genzyme and Amgen, Advisory Board for Celgene and Janssen-Cilag; A Palumbo: Advisory Board for Ortho Biotech and Celgene; W Bensinger: Advisory Board for Celgene and Millennium, Research funding from Genzyme, Millennium, Celgene, AstraZeneca and Novartis; R Comenzo: Advisory Board for Millennium and Ortho Biotech; S Kumar: Clinical trial funding from Celgene, Millennium, Genzyme; N Munshi: Advisory Board for Celgene; R Kyle: No disclosures; J San Miguel: Advisory Board for Millennium, Janssen-Cilag, and Celgene; H Ludwig: Clinical trial funding from Schering-Plough, Janssen-Cilag, and participation in Speaker{\textquoteright}s Bureau for Amgen, Roche, Janssen-Cilag; J Blade: Honorarium for lectures and Advisory Board for Celgene, Janssen-Cilag. Research grant from Celgene; S Lonial: Consultant for Millennium, Celgene, Novartis, and BMS; H Einsele: Advisory Board for Celgene and Ortho Biotech; P Tosi: No disclosures; P Sonneveld: Advisory Board for Ortho Biotech and Celege; O Sezer: Clinical trial/research funding from Janssen-Cilag, Merck, and Novartis. Speaker{\textquoteright}s Bureau for Amgen, Celgene, Merck, Novartis, Ortho Biotech, Pharmion, and Roche; M Cavo: No disclosures; P Richardson: Advisory Board for Celgene and Millennium; SV Rajkumar: No disclosures; B Durie: Advisory Board for Celgene and Millennium.",
year = "2009",
doi = "10.1038/leu.2009.127",
language = "English (US)",
volume = "23",
pages = "1904--1912",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Nature Publishing Group",
number = "10",
}